Medicinal Chemistry, small molecule drugs, Heterocyclic drugs, Covid-19, SARS-COV-2, Corona Virus, Viral infections, Viral therapeutics
The SARS-CoV-2 outbreak and subsequent pandemic that began in late 2019 has presented a significant challenge to global health. Currently, numerous small-molecule therapeutic candidates have been developed that can inhibit both the infection and replication of SARS-CoV-2, and may even alleviate cytokine storms and related complications. Additionally, host-targeted drugs that inhibit the cellular transmembrane serine protease (TMPRSS2) can block SARS-CoV-2 from entering cells. When used in combination with chloroquine and dihydroorotate dehydrogenase (DHODH) inhibitors, these therapies can limit the spread of SARS-CoV-2 and reduce the morbidity and mortality of COVID-19 patients. This article provides a comprehensive overview of these small-molecule therapeutics, drawing on insights from medicinal chemistry research. It focuses on RNA-dependent RNA polymerase (RdRp) inhibitors, such as nucleoside analogues like remdesivir, favipiravir, and ribavirin. The review also examines inhibitors of 3C-like protease (3CLpro), papain-like protease (PLpro), and other potentially innovative active ingredient molecules, discussing their targets, activities, clinical status, and side effects.
The SARS-CoV-2 outbreak and subsequent pandemic that began in late 2019 has presented a significant challenge to global health. Currently, numerous small-molecule therapeutic candidates have been developed that can inhibit both the infection and replication of SARS-CoV-2, and may even alleviate cytokine storms and related complications. Additionally, host-targeted drugs that inhibit the cellular transmembrane serine protease (TMPRSS2) can block SARS-CoV-2 from entering cells. When used in combination with chloroquine and dihydroorotate dehydrogenase (DHODH) inhibitors, these therapies can limit the spread of SARS-CoV-2 and reduce the morbidity and mortality of COVID-19 patients. This article provides a comprehensive overview of these small-molecule therapeutics, drawing on insights from medicinal chemistry research. It focuses on RNA-dependent RNA polymerase (RdRp) inhibitors, such as nucleoside analogues like remdesivir, favipiravir, and ribavirin. The review also examines inhibitors of 3C-like protease (3CLpro), papain-like protease (PLpro), and other potentially innovative active ingredient molecules, discussing their targets, activities, clinical status, and side effects.
Journal of Molecular Chemistry
Discover more from RSYN FYI
Subscribe to get the latest posts sent to your email.